AArtificial intelligence Read More Meta’s Chief AI Scientist is leaving the company after 12 yearsNovember 20, 2025 One of Meta’s top AI researchers, Yann LeCun, is leaving after 12 years with the company to found…
HHealthcare Read More BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s DiseaseNovember 12, 2025 BioXcel Therapeutics sNDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based…
CComputing Read More D-Wave Quantum (QBTS) Announces First-Ever Qubits Japan 2025 Quantum Computing User ConferenceSeptember 17, 2025 LOS ANGELES, CA – September 17, 2025 (NEWMEDIAWIRE) – D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or “The Company”),…
IInternet Read More Kinetic Wins State Approvals of $156 Million in BEAD Grants to Expand Multi-Gig Fiber BroadbandSeptember 13, 2025 Almost 52,000 rural homes and businesses in four states will get access to fiber connections LITTLE ROCK, Ark.,…
HHealthcare Read More BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or SchizophreniaSeptember 10, 2025 BioXcel Therapeutics BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2…
HHealthcare Read More BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®August 30, 2025 BioXcel Therapeutics BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation…
HHealthcare Read More BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025August 26, 2025 BioXcel Therapeutics Company to host conference call at 8 a.m. ET, August 27, 2025 NEW HAVEN, Conn., Aug.…
HHealthcare Read More BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaAugust 22, 2025 BioXcel Therapeutics Data from more than 2,600 agitation episodes collected Topline data readout is on track for August …
CComputing Read More Quantum Computing Inc. Reports Second Quarter 2025 Financial ResultsAugust 16, 2025 HOBOKEN, N.J., Aug. 14, 2025 /PRNewswire/ — Quantum Computing Inc. (“QCi” or the “Company”) (Nasdaq: QUBT), an innovative, integrated…